Condition: Acute Coronary Syndromes (ACS) · Recent Myocardial Infarction · Recent Stroke · Sponsor: Shanghai CureGene Pharmaceutical Co., Ltd.
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.
This description comes directly from the study's public registry record.
Isabel Pino · 305-547-5813 · Isabel.pino@syneoshealth.com
Always discuss trial participation with your own doctor first.
| Syneos Health | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07619885